Lantheus Medical Imaging Presents Phase 4 Safety Data on DEFINITY(R) at American Society of Echocardiography Annual Meeting

NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic medical imaging, today announced new data from a Phase 4, open-label safety study evaluating the effect of DEFINITY® Vial For (Perflutren Lipid Microsphere) Injectable Suspension, an echocardiography contrast agent, on pulmonary and systemic artery hemodynamics in patients with either normal or increased baseline pulmonary artery pressure. The study demonstrated that administration of DEFINITY® did not result in any clinically or statistically significant changes in systemic or pulmonary artery hemodynamic measurements in either patient group. The data were presented on Sunday, June 13, 2010, by Kevin Wei, M.D., Associate Professor of Medicine at Oregon Health & Science University, during the “Contrast Perfusion Imaging in Decision-Making” case-based presentation at the American Society of Echocardiography 21st Annual Scientific Sessions in San Diego.